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ABSTRACT
Metabolic rearrangements and genome instability are two hallmarks of cancer. Recent evidence from
our laboratory demonstrates that persistent DNA lesions hampering transcription may cause glucose
rerouting through the pentose phosphate shunt and reductive stress. Here, we highlight the relevance
of these findings for cancer and chemoresistance development.
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Cancer cells display distinctive biological features – for instance,
extremely high rates of nucleic acid synthesis – that may be
sustainable only under certain specific metabolic conditions.
Consistently, alterations in metabolism are hallmarks of cancer,
as notably exemplified by the Warburg effect. Genome instability
is another distinctive feature of cancer; increased DNA damage
burden and defects in DNA repair are fundamental causative
elements in carcinogenesis, underlie the extreme clonal variability
in tumors, and are major determinant of chemoresistance.
Genome instability and metabolic alterations are inter-
twisted characteristics of cancer and evidence principally
gained at transcriptional level revealed differences in the
metabolic layout of organisms with defective DNA repair.
Changes in mRNA levels, however, are not sufficient to pro-
vide an accurate depiction of the metabolic landscape, which
is largely modulated by allosteric regulation, independently
from both transcription and translation.
In a recent study, we characterized metabolic rearrangements
occurring in mouse models and patients’ specimen with
impaired transcription-coupled- and global-genome-nucleotide
excision repair (TC-NER and GG-NER, respectively). Here, we
described a mechanism connecting transcription stalling caused
by defective DNA repair with augmented intracellular ATP
levels, which in turn allosterically inhibit the glycolytic enzyme
ATP-dependent 6-phosphofructokinase (Pfk, best known as
phosphofructokinase) to reroute glucose through the pentose
phosphate pathway (PPP). Potentiation of the PPP is intrinsi-
cally associated with increased production of NADPH reducing
equivalents – which are generated in the oxidative branch of the
pathway – that in our experimental system is not paralleled by
proportionate production of oxidant species and/or endogenous
oxidoreductase activity, and therefore culminates in reductive
stress1 (Figure 1A).
GG-NER defects cause cancer and imperfect TC-NER pro-
motes aging – i.e. the major risk factor for cancer; moreover,
chemicals inducing NER amended DNA lesions that also
block transcription are currently used in clinical practice as
chemotherapeutic drugs. Our findings may therefore be of
particular relevance in the processes of carcinogenesis,
tumor growth, and chemoresistance (Figure 1B).
Activation of the PPPmay promote survival of cancer cells.2 In
rapidly dividing cells, the vast majority of pentose phosphate
sugars and ribonucleotides incorporated in DNA are products
of the PPP, as demonstrated by elegant 13C-tracing experiments.3
PPP potentiation may therefore represent an undesired effect of
DNA-damage-inducing therapies leading to higher bioavailability
of nucleic acids, which could help sustaining fast replication in
resistant clones. In line with this concept, multiple factors impor-
tant for carcinogenesis and/or chemoresistance – including, but
not limited to suppression of tumor protein p53 (TP53, best
known as p53) and activation of ataxia telangiectasia mutated
(ATM)4,5 – positively regulate the PPP. Moreover, proper func-
tion of the PPP is essential for cancer proliferation, at least in some
cases, because inactive 6-phoshogluconate dehydrogenase
(6PGD) – which is part of the PPP oxidative branch – causes
senescence in lung carcinoma.6 This effect is partially mediated by
reduced redox buffering capacity and by increased oxidant stress,
which are known causes of senescence.
According to our model, DNA-damage-induced transcrip-
tion block is not per se sufficient to activate the PPP and also
requires high ATP levels. In our experimental paradigm – i.e.
defective TC- and GG-NER caused by a truncation in the exci-
sion repair cross complementation group 1 gene (Ercc1) – aug-
mented intracellular ATP concentration is caused by a decline in
macromolecular synthesis, i.e. a highly demanding process from
the bioenergetics standpoint. Because cancer cells are character-
ized by extreme rates of DNA synthesis, one could argue that
ATP surplus is unlikely to occur under these circumstances. In
cancer, however, there are cases that could conceivably be asso-
ciated with macromolecular synthesis reduction. For instance, at
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very initial stages of carcinogenesis, when replication is not yet
rampant, transcription stalling DNA damage caused by intrinsic
genome instability may be associated with ATP level sufficient to
inhibit glycolysis. A further possibility stems from recent evi-
dence supporting the concept that development of chemoresis-
tance may parallel development of antibiotic resistance in
bacteria.7 Here, in initial phases, growth – and thus macromo-
lecular synthesis – is highly reduced in resistant cells. These
circumstances may promote transient high levels of ATP that
could temporarily potentiate the PPP and oxidant defenses in
those clones that will resist treatment. Consistently, recent stu-
dies based on ultra-short 13C tracing experiments indicate that
glucose rerouting through the PPP represents an immediate and
necessary response to oxidant-stress in skin fibroblasts and
suggest that PPP activation may participate in development of
resistance to therapies based on stimulation of toxic reactive
oxygen species (ROS) production.8 Intervening on these
processes to halt PPP potentiation may therefore offer interest-
ing therapeutic perspectives to improve current chemotherapy
approaches.
Our study reveals that glucose rerouting through the PPP in
TC-NER and GG-NER defective specimens culminates in reduc-
tive stress. The latter deserves special mention because – differ-
ently than oxidative stress – it has not received adequate
investigative attention. Thus, despite unambiguous evidence
demonstrating that excessive reducing capacity is detrimental,
our understanding of reductive stress is still highly rudimentary.
It is only very recently that redox biology has been approached
more holistically – beyond the traditional oxidative stress con-
cept – recognizing the importance of alterations in redox couples
caused not only by excess of oxidants, but also by a reducing
equivalent surplus.9 While further investigative efforts are
required to characterize the biological impact of reductive stress,
some consequences may be envisaged to be very relevant for
Figure 1. Metabolic rewiring caused by transcription-stalling DNA damage and its contribution to tumor chemoresistance. (A) Cascade of events leading to reductive
stress upon accumulation of transcription-blocking DNA damage that causes stalling of the multi-protein complex RNA polymerase II (RNA pol II), reduced
transcription output, and thus decreased macromolecular synthesis. These alterations culminate in augmented concentrations of ATP that inhibit the glycolytic
enzyme ATP-dependent 6-phosphofructokinase (PFK, best known as phosphofructokinase) via allosteric mechanisms. Glucose is therefore diverted through the
pentose phosphate pathway (PPP), with consequent increased production of NADPH that increases the reductive capacity of the cell. In the absence of
commensurate pro-oxidant factors, the latter culminates in reductive stress (RNA pol II structure PDB code: 1i6h). (B) DNA-damage induces potentiation of the
PPP and reductive stress, which may contribute to carcinogenesis and chemoresistance. (i) DNA damage could lead to the development of cancer cells via lesions that
also induce transcription stalling. In cases where the DNA damage burden is not yet sufficient to miss checkpoints, and therefore if replication is not yet rampant,
transcription stalling may lead to transient increased ATP concentration, glucose rerouting through the PPP, and reductive stress, which could provide these clones
with increased fitness. Comparable phenomena may occur during chemotherapy; (ii) resistant clones, which may exhibit lower replication rates, use transient ATP
surplus to reroute glucose through the PPP, to increase cellular reductive capacity, and to improve to clonal fitness. These metabolic rearrangements may ultimately
favor chemoresistance.
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cancer. For instance, reduction in the NAD(P)H/NAD(P)+ redox
couple – similarly to what we detected upon persistent transcrip-
tion stalling – occurs also during hypoxia,10 which is a major
complication of cancer that severely aggravates prognosis. It is
tempting to hypothesize that – during DNA damage-based che-
motherapy – persistent transcription stalling in slow-growing,
potentially resistant clones may cause a detrimental metabolic
phenotype that parallels hypoxia.
Overall, we believe that our findings provide novel hints on the
possible consequences of DNA-repair-driven metabolic redesign
on cancer. Obviously, further studies are warranted to verify the
relevance of our model for cancer and to test whether interven-
tions targeting glucose rerouting, PPP activation, and excessive
reductive capacity may constitute amenable strategies to treat
cancer.
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